de Verneuil Vanina 4
4 · Vir Biotechnology, Inc. · Filed Feb 24, 2026
Insider Transaction Report
Form 4
de Verneuil Vanina
EVP, General Counsel, Corp Sec
Transactions
- Award
Common Stock
[F1][F2]2026-02-22+55,000→ 134,244 total - Sale
Common Stock
[F3]2026-02-23$7.45/sh−4,445$33,128→ 129,799 total - Award
Stock Option (Right to Buy)
[F4]2026-02-22+110,000→ 110,000 totalExercise: $7.56Exp: 2036-02-21→ Common Stock (110,000 underlying)
Footnotes (4)
- [F1]Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- [F2]Includes 1,034 shares of common stock acquired by the Reporting Person on November 28, 2025 pursuant to an employee stock purchase program.
- [F3]Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.
- [F4]25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.
Signature
/s/ Lorin Wagner, Attorney-In-Fact|2026-02-24